Author details

Full Name

Sijy O'Dell

Affiliation

ORCID

Career Start Year

2004

Papers

112

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
36265510	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.	Nat Med	2023
37989731	Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.		2023
37986823	Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.	bioRxiv	2023
37436900	Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.		2023
37436899	HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.	Cell Rep	2023
35081298	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.	N Engl J Med	2022
35447072	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.	Cell	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
35378757	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	bioRxiv	2022
35547849	Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis.		2022
36263060	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.	bioRxiv	2022
36423012	Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1.	Vaccines	2022
36517467	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	Nat Commun	2022
34931200	Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.	medRxiv	2021
34210892	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.	Science	2021
34200826	Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography.	Antibodies (Basel)	2021
33826898	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base.	Cell Reports	2021
34031659	Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.	bioRxiv	2021
33822494	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.	New England Journal of Medicine	2021
33649208	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.	Proc Natl Acad Sci U S A	2021
33270381	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.	N Engl J Med	2021
34672695	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.	Science	2021
34559844	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization.	PLoS Pathog	2021
34426813	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.	bioRxiv	2021
32663912	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.	N Engl J Med	2020
32130953	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.	Cell Host Microbe	2020
32066595	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.	Journal of Immunology	2020
31704807	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses.	J Exp Med	2020
32991794	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.	N Engl J Med	2020
32755575	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.	Cell Rep	2020
33121334	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies.	mAbs	2020
32722908	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.	N Engl J Med	2020
30995238	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.	PLoS One	2019
31732167	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.	Immunity	2019
30604750	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.	Nature Communications	2019
31348886	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.	Cell	2019
29548671	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.	Immunity	2018
29867235	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.	Nat Med	2018
29491415	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.	Nature Communications	2018
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
28275193	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.	Journal of Virology	2017
28825711	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.	Nature Chemical Biology	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
28931639	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.	Science	2017
28835491	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.	Journal of Virology	2017
28783671	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.	Science immunology	2017
28514687	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.	Immunity	2017
28514685	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.	Immunity	2017
28052137	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.	PLoS Pathog	2017